Welcome to the ultimate men’s self-improvement community where like-minded individuals come together to level up every aspect of their lives. Whether it’s building confidence, improving your mindset, optimizing health, or mastering aesthetics, this is the place to become the best version of yourself. Join the hood and start your transformation today.
1. HISTORICAL AND CLINICAL CONTEXT Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) was originally synthesized in the 1970s by the Upjohn Company (now Pfizer) as a peripheral vasodilator for severe, refractory hypertension. Its mechanism was basically opening ATP sensitive potassium channels (KATP) in vascular smooth muscle reducing systemic vascular resistance with minimal direct cardiac depression.
observation: within 3 to 6 months of oral administration the patients developed generalized hypertrichosis (excessive body hair), most pronounced on the face, arms and back. this side effect was dose dependent and reversible upon discontinuation.
subsequent topical formulation development (2%, 5%, 5% foam and 15% compounded solutions) targeted the scalp while minimizing systemic absorption. FDA approval for androgenetic alopecia occurred in 1988 (2%) and 1997 (5% for men and 2% for women).
clinical distinction: minoxidil is not an antiandrogen. It doesnt inhibit 5AR nor does it block the androgen receptor. It works entirely independently of the hormonal axis which explains why it is effective in both androgenic alopecia and alopecia areata albeit through completely different pathophysiological routes.
2. CHEMICAL STRUCTURE AND PRODRUG ACTIVATION
minoxidil as administered is a prodrug. It has negligible biological activity in its native form.
Structural features:
I) pyrimidine N-oxide (the 3-oxide group is critical for subsequent sulfation)
II) primary amine at position 2 and 4 (diamino)
III) piperidine ring at position 6
Pathway for bioactivation:
Minoxidil to Minoxidil sulfate (active form) via sulfotransferase enzymes, specifically SULT1A1 (cytosolic and phenol preferring) and maybe SULT1A3 in some tissues
The reaction transfers a sulfonate group (SO₃-) from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the N-oxide oxygen of minoxidil. the resulting minoxidil N-O-sulfate is a stable anion at physiological pH
Tissue specificity of activation:
Highest SULT1A1 expression is in liver (first pass metabolism), kidney, intestinal mucosa, dermal papilla cells and outer root sheath keratinocytes of the hair follicle
SULT1A1 activity varies interindividually by upto 10 fold due to genetic polymorphisms (like the SULT1A12 variant, R213H, reduces activity)
Why this matters:
non responders to topical minoxidil often have low SULT1A1 activity in scalp follicles. coadministration of tret upregulates SULT1A1 expression and minoxidil sulfation in vitro.
3. ION CHANNEL PHYSIOLOGY (KATP)
The primary established molecular target of minoxidil sulfate is the ATP sensitive potassium channel (KATP).
3.1 Channel Structure
KATP is an octameric complex of two distinct subunits: I) Kir6.0 (KCNJ8 for Kir6.1, KCNJ11 for Kir6.2): this one forms the potassium conducting pore. has a tetrameric assembly. II) SUR (sulfonylurea receptor, ABCC8 for SUR1, ABCC9 for SUR2): it's a regulatory subunit belonging to the ATP binding cassette (ABC) transporter family. binds nucleotides (ATP/ADP) and channel openers (including minoxidil sulfate, cromakalim, diazoxide)
Four SUR subunits associate with four Kir6.0 subunits (SURx4/Kir6.x4).
The relevant isoform for hair growth is SUR2B/Kir6.1 on dermal papilla cells (DPCs) and to a lesser extent outer root sheath keratinocytes
3.3 Mechanism of Channel Opening
Under normal physiological conditions, intracellular ATP closes KATP (that is why it's “ATP sensitive” lmao). high ATP/ADP ratio makes the channel close so the membrane gets depolarized. low ATP/ADP ratio causes channel to open which leads to hyperpolarization
Minoxidil sulfate binds to the SUR2B subunit at a site distinct from the nucleotide binding folds (specifically transmembrane helices 8-11 of SUR2).
Binding:
I) displaces inhibitory Mg ATP from SUR’s NBF2 (nucleotide binding fold 2)
II) stabilizes the open conformation of Kir6.1
III) allows potassium efflux even at normal or elevated ATP levels
4. THE VEGF AXIS
Minoxidil promotes angiogenesis in the dermal papilla and perifollicular microvasculatur independent of KATP opening
4.1 VEGF-A Upregulation
Vascular endothelial growth factor (VEGF-A) is a super important paracrine signal from DPCs to endothelial cells of the perifollicular capillary plexus. Minoxidil increases VEGF-A mRNA and protein in cultured DPCs within around 10 hrs i guess.
Mechanism (proposed):
I) Minoxidil sulfate inhibits lysyl hydroxylase (procollagen-lysine, 2-oxoglutarate 5-dioxygenase, PLOD). This enzyme hydroxylates lysine residues in collagen so inhibition leads to unfolded protein response (UPR) and activation of hypoxia inducible factor 1α (HIF 1 alpha)
II) HIF-1α escapes von Hippel-Lindau (VHL) mediated proteasomal degradation then translocates to the nucleus and binds hypoxia response elements (HREs) in the VEGF-A promoter.
III) This mimics a hypoxic state without actual oxygen deprivation
4.2 Prostaglandin Synthesis
Minoxidil also increases cyclooxygenase-1 (COX-1) activity in DPCs leading to elevated prostaglandin E2 (PGE2) and prostacyclin (PGI2). Both PGE2 and PGI2 are vasodilatory and pro angiogenic via EP2/EP4 and IP receptors.
4.3 Relevance to Hair Cycling
Anagen requires a dense perifollicular capillary network. during the transition from telogen to anagen angiogenesis precedes keratinocyte proliferation. minoxidil likely shortens the telogen-to-anagen transition time via VEGF mediated vascular remodeling
5. PROLONGATION OF ANAGEN PHASE
The hair cycle consists of three phases: anagen (growth), catagen (apoptosis driven regression), telogen (resting). In AGA, anagen progressively shortens with each cycle producing miniaturized vellus hairs.
5.1 Apoptosis Suppression
Minoxidil delays catagen entry by inhibiting programmed cell death in follicular keratinocytes.
Molecular mechanisms:
I) Increases Bcl-2/Bax ratio (anti apoptotic Bcl-2 upregulated and pro apoptotic Bax unchanged or slightly reduced).
II) Reduces caspase-3 activation (executioner caspase).
III) Suppresses p53-dependent apoptosis (p53 is a catagen triggering transcription factor in the follicle).
5.2 Matrix Keratinocyte Proliferation
Minoxidil directly stimulates proliferation of outer root sheath (ORS) keratinocytes and matrix cells in the hair bulb. this effect is independent of KATP (Kir6.1 is low in these cells) and instead mediated by:
I) ERK1/2 (MAPK pathway) activation (phosphorylation at Thr202/Tyr204).
II) PI3K/AKT pathway activation (phosphorylation at Ser473).
Both pathways converge on cyclin D1 upregulation promoting G1/S transition.
6. β-CATENIN AND Wnt PATHWAY MODULATION
The canonical Wnt/β-catenin pathway is the master regulator of hair follicle morphogenesis and cycling. β-catenin stabilization in dermal papilla cells and keratinocytes is necessary and sufficient to induce anagen.
6.1 Mechanism of β-Catenin Stabilization
In the absence of Wnt signaling a destruction complex (Axin, APC, GSK3β, CK1α) phosphorylates β-catenin at Ser33/Ser37/Thr41 leading to ubiquitination (β-TrCP) and proteasomal degradation.
minox promotes β-catenin stabilization via: I) Inhibition of GSK3β (glycogen synthase kinase 3β) II) Reduced phosphorylation at Ser33/Ser37
Stabilized β-catenin translocates to the nucleus and complexes with TCF/LEF (T cell factor/lymphoid enhancer factor) transcription factors. the target genes are: I) Axin2 (negative feedback loop) II) Cyclin D1 (proliferation) III) LEF1 itself (positive feedback) IV) FGF18 (anagen maintenance and not initiation)
In the absence of Wnt signaling (or with minoxidil) hair follicles remain in telogen. Minoxidil induced β-catenin stabilization maybe sufficient to overcome endogenous Wnt inhibitors (DKK1, SFRP1) that are elevated in balding scalps
7. MITOCHONDRIAL BIOGENESIS AND PGC-1α
a more recently described effect: minoxidil increases mitochondrial content and function in dermal papilla cells.
here PGC-1α (peroxisome proliferator activated receptor gamma coactivator 1-alpha) is the master regulator of mitochondrial biogenesis.
Mechanism:
I) Minoxidil elevates intracellular NAD+/NADH ratio
II) Increased NAD+ activates SIRT1 (sirtuin 1) which is an NAD+ dependent deacetylase.
III) SIRT1 deacetylates and activates PGC-1α.
IV) Activated PGC-1α coactivates NRF1 (nuclear respiratory factor 1) and NRF2 which drive transcription of mitochondrial DNA encoded genes (COX1, COX2, ATP6) and nuclear encoded mitochondrial genes (TFAM, TFB1M, TFB2M).
Consequence in DPCs: higher mitochondrial density supports the high metabolic demand of anagen phase follicles. DPCs from balding scalps show reduced mitochondrial membrane potential and increased ROS which minoxidil partially reverses
1. HISTORICAL AND CLINICAL CONTEXT Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) was originally synthesized in the 1970s by the Upjohn Company (now Pfizer) as a peripheral vasodilator for severe, refractory hypertension. Its mechanism was basically opening ATP sensitive potassium channels (KATP) in vascular smooth muscle reducing systemic vascular resistance with minimal direct cardiac depression.
observation: within 3 to 6 months of oral administration the patients developed generalized hypertrichosis (excessive body hair), most pronounced on the face, arms and back. this side effect was dose dependent and reversible upon discontinuation.
subsequent topical formulation development (2%, 5%, 5% foam and 15% compounded solutions) targeted the scalp while minimizing systemic absorption. FDA approval for androgenetic alopecia occurred in 1988 (2%) and 1997 (5% for men and 2% for women).
clinical distinction: minoxidil is not an antiandrogen. It doesnt inhibit 5AR nor does it block the androgen receptor. It works entirely independently of the hormonal axis which explains why it is effective in both androgenic alopecia and alopecia areata albeit through completely different pathophysiological routes.
2. CHEMICAL STRUCTURE AND PRODRUG ACTIVATION
minoxidil as administered is a prodrug. It has negligible biological activity in its native form.
Structural features:
I) pyrimidine N-oxide (the 3-oxide group is critical for subsequent sulfation)
II) primary amine at position 2 and 4 (diamino)
III) piperidine ring at position 6
Pathway for bioactivation:
Minoxidil to Minoxidil sulfate (active form) via sulfotransferase enzymes, specifically SULT1A1 (cytosolic and phenol preferring) and maybe SULT1A3 in some tissues
The reaction transfers a sulfonate group (SO₃-) from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the N-oxide oxygen of minoxidil. the resulting minoxidil N-O-sulfate is a stable anion at physiological pH
Tissue specificity of activation:
Highest SULT1A1 expression is in liver (first pass metabolism), kidney, intestinal mucosa, dermal papilla cells and outer root sheath keratinocytes of the hair follicle
SULT1A1 activity varies interindividually by upto 10 fold due to genetic polymorphisms (like the SULT1A12 variant, R213H, reduces activity)
Why this matters:
non responders to topical minoxidil often have low SULT1A1 activity in scalp follicles. coadministration of tret upregulates SULT1A1 expression and minoxidil sulfation in vitro.
3. ION CHANNEL PHYSIOLOGY (KATP)
The primary established molecular target of minoxidil sulfate is the ATP sensitive potassium channel (KATP).
3.1 Channel Structure
KATP is an octameric complex of two distinct subunits: I) Kir6.0 (KCNJ8 for Kir6.1, KCNJ11 for Kir6.2): this one forms the potassium conducting pore. has a tetrameric assembly. II) SUR (sulfonylurea receptor, ABCC8 for SUR1, ABCC9 for SUR2): it's a regulatory subunit belonging to the ATP binding cassette (ABC) transporter family. binds nucleotides (ATP/ADP) and channel openers (including minoxidil sulfate, cromakalim, diazoxide)
Four SUR subunits associate with four Kir6.0 subunits (SURx4/Kir6.x4).
The relevant isoform for hair growth is SUR2B/Kir6.1 on dermal papilla cells (DPCs) and to a lesser extent outer root sheath keratinocytes
3.3 Mechanism of Channel Opening
Under normal physiological conditions, intracellular ATP closes KATP (that is why it's “ATP sensitive” lmao). high ATP/ADP ratio makes the channel close so the membrane gets depolarized. low ATP/ADP ratio causes channel to open which leads to hyperpolarization
Minoxidil sulfate binds to the SUR2B subunit at a site distinct from the nucleotide binding folds (specifically transmembrane helices 8-11 of SUR2).
Binding:
I) displaces inhibitory Mg ATP from SUR’s NBF2 (nucleotide binding fold 2)
II) stabilizes the open conformation of Kir6.1
III) allows potassium efflux even at normal or elevated ATP levels View attachment 54041
4. THE VEGF AXIS
Minoxidil promotes angiogenesis in the dermal papilla and perifollicular microvasculatur independent of KATP opening
4.1 VEGF-A Upregulation
Vascular endothelial growth factor (VEGF-A) is a super important paracrine signal from DPCs to endothelial cells of the perifollicular capillary plexus. Minoxidil increases VEGF-A mRNA and protein in cultured DPCs within around 10 hrs i guess.
Mechanism (proposed):
I) Minoxidil sulfate inhibits lysyl hydroxylase (procollagen-lysine, 2-oxoglutarate 5-dioxygenase, PLOD). This enzyme hydroxylates lysine residues in collagen so inhibition leads to unfolded protein response (UPR) and activation of hypoxia inducible factor 1α (HIF 1 alpha)
II) HIF-1α escapes von Hippel-Lindau (VHL) mediated proteasomal degradation then translocates to the nucleus and binds hypoxia response elements (HREs) in the VEGF-A promoter.
III) This mimics a hypoxic state without actual oxygen deprivation
4.2 Prostaglandin Synthesis
Minoxidil also increases cyclooxygenase-1 (COX-1) activity in DPCs leading to elevated prostaglandin E2 (PGE2) and prostacyclin (PGI2). Both PGE2 and PGI2 are vasodilatory and pro angiogenic via EP2/EP4 and IP receptors.
4.3 Relevance to Hair Cycling
Anagen requires a dense perifollicular capillary network. during the transition from telogen to anagen angiogenesis precedes keratinocyte proliferation. minoxidil likely shortens the telogen-to-anagen transition time via VEGF mediated vascular remodeling
5. PROLONGATION OF ANAGEN PHASE
The hair cycle consists of three phases: anagen (growth), catagen (apoptosis driven regression), telogen (resting). In AGA, anagen progressively shortens with each cycle producing miniaturized vellus hairs.
5.1 Apoptosis Suppression
Minoxidil delays catagen entry by inhibiting programmed cell death in follicular keratinocytes.
Molecular mechanisms:
I) Increases Bcl-2/Bax ratio (anti apoptotic Bcl-2 upregulated and pro apoptotic Bax unchanged or slightly reduced).
II) Reduces caspase-3 activation (executioner caspase).
III) Suppresses p53-dependent apoptosis (p53 is a catagen triggering transcription factor in the follicle).
5.2 Matrix Keratinocyte Proliferation
Minoxidil directly stimulates proliferation of outer root sheath (ORS) keratinocytes and matrix cells in the hair bulb. this effect is independent of KATP (Kir6.1 is low in these cells) and instead mediated by:
I) ERK1/2 (MAPK pathway) activation (phosphorylation at Thr202/Tyr204).
II) PI3K/AKT pathway activation (phosphorylation at Ser473).
Both pathways converge on cyclin D1 upregulation promoting G1/S transition. View attachment 54045
6. β-CATENIN AND Wnt PATHWAY MODULATION
The canonical Wnt/β-catenin pathway is the master regulator of hair follicle morphogenesis and cycling. β-catenin stabilization in dermal papilla cells and keratinocytes is necessary and sufficient to induce anagen.
6.1 Mechanism of β-Catenin Stabilization
In the absence of Wnt signaling a destruction complex (Axin, APC, GSK3β, CK1α) phosphorylates β-catenin at Ser33/Ser37/Thr41 leading to ubiquitination (β-TrCP) and proteasomal degradation.
minox promotes β-catenin stabilization via: I) Inhibition of GSK3β (glycogen synthase kinase 3β) II) Reduced phosphorylation at Ser33/Ser37
Stabilized β-catenin translocates to the nucleus and complexes with TCF/LEF (T cell factor/lymphoid enhancer factor) transcription factors. the target genes are: I) Axin2 (negative feedback loop) II) Cyclin D1 (proliferation) III) LEF1 itself (positive feedback) IV) FGF18 (anagen maintenance and not initiation)
In the absence of Wnt signaling (or with minoxidil) hair follicles remain in telogen. Minoxidil induced β-catenin stabilization maybe sufficient to overcome endogenous Wnt inhibitors (DKK1, SFRP1) that are elevated in balding scalps View attachment 54046
7. MITOCHONDRIAL BIOGENESIS AND PGC-1α
a more recently described effect: minoxidil increases mitochondrial content and function in dermal papilla cells.
here PGC-1α (peroxisome proliferator activated receptor gamma coactivator 1-alpha) is the master regulator of mitochondrial biogenesis.
Mechanism:
I) Minoxidil elevates intracellular NAD+/NADH ratio
II) Increased NAD+ activates SIRT1 (sirtuin 1) which is an NAD+ dependent deacetylase.
III) SIRT1 deacetylates and activates PGC-1α.
IV) Activated PGC-1α coactivates NRF1 (nuclear respiratory factor 1) and NRF2 which drive transcription of mitochondrial DNA encoded genes (COX1, COX2, ATP6) and nuclear encoded mitochondrial genes (TFAM, TFB1M, TFB2M).
Consequence in DPCs: higher mitochondrial density supports the high metabolic demand of anagen phase follicles. DPCs from balding scalps show reduced mitochondrial membrane potential and increased ROS which minoxidil partially reverses View attachment 54052
1. HISTORICAL AND CLINICAL CONTEXT Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) was originally synthesized in the 1970s by the Upjohn Company (now Pfizer) as a peripheral vasodilator for severe, refractory hypertension. Its mechanism was basically opening ATP sensitive potassium channels (KATP) in vascular smooth muscle reducing systemic vascular resistance with minimal direct cardiac depression.
observation: within 3 to 6 months of oral administration the patients developed generalized hypertrichosis (excessive body hair), most pronounced on the face, arms and back. this side effect was dose dependent and reversible upon discontinuation.
subsequent topical formulation development (2%, 5%, 5% foam and 15% compounded solutions) targeted the scalp while minimizing systemic absorption. FDA approval for androgenetic alopecia occurred in 1988 (2%) and 1997 (5% for men and 2% for women).
clinical distinction: minoxidil is not an antiandrogen. It doesnt inhibit 5AR nor does it block the androgen receptor. It works entirely independently of the hormonal axis which explains why it is effective in both androgenic alopecia and alopecia areata albeit through completely different pathophysiological routes.
2. CHEMICAL STRUCTURE AND PRODRUG ACTIVATION
minoxidil as administered is a prodrug. It has negligible biological activity in its native form.
Structural features:
I) pyrimidine N-oxide (the 3-oxide group is critical for subsequent sulfation)
II) primary amine at position 2 and 4 (diamino)
III) piperidine ring at position 6
Pathway for bioactivation:
Minoxidil to Minoxidil sulfate (active form) via sulfotransferase enzymes, specifically SULT1A1 (cytosolic and phenol preferring) and maybe SULT1A3 in some tissues
The reaction transfers a sulfonate group (SO₃-) from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the N-oxide oxygen of minoxidil. the resulting minoxidil N-O-sulfate is a stable anion at physiological pH
Tissue specificity of activation:
Highest SULT1A1 expression is in liver (first pass metabolism), kidney, intestinal mucosa, dermal papilla cells and outer root sheath keratinocytes of the hair follicle
SULT1A1 activity varies interindividually by upto 10 fold due to genetic polymorphisms (like the SULT1A12 variant, R213H, reduces activity)
Why this matters:
non responders to topical minoxidil often have low SULT1A1 activity in scalp follicles. coadministration of tret upregulates SULT1A1 expression and minoxidil sulfation in vitro.
3. ION CHANNEL PHYSIOLOGY (KATP)
The primary established molecular target of minoxidil sulfate is the ATP sensitive potassium channel (KATP).
3.1 Channel Structure
KATP is an octameric complex of two distinct subunits: I) Kir6.0 (KCNJ8 for Kir6.1, KCNJ11 for Kir6.2): this one forms the potassium conducting pore. has a tetrameric assembly. II) SUR (sulfonylurea receptor, ABCC8 for SUR1, ABCC9 for SUR2): it's a regulatory subunit belonging to the ATP binding cassette (ABC) transporter family. binds nucleotides (ATP/ADP) and channel openers (including minoxidil sulfate, cromakalim, diazoxide)
Four SUR subunits associate with four Kir6.0 subunits (SURx4/Kir6.x4).
The relevant isoform for hair growth is SUR2B/Kir6.1 on dermal papilla cells (DPCs) and to a lesser extent outer root sheath keratinocytes
3.3 Mechanism of Channel Opening
Under normal physiological conditions, intracellular ATP closes KATP (that is why it's “ATP sensitive” lmao). high ATP/ADP ratio makes the channel close so the membrane gets depolarized. low ATP/ADP ratio causes channel to open which leads to hyperpolarization
Minoxidil sulfate binds to the SUR2B subunit at a site distinct from the nucleotide binding folds (specifically transmembrane helices 8-11 of SUR2).
Binding:
I) displaces inhibitory Mg ATP from SUR’s NBF2 (nucleotide binding fold 2)
II) stabilizes the open conformation of Kir6.1
III) allows potassium efflux even at normal or elevated ATP levels View attachment 54041
4. THE VEGF AXIS
Minoxidil promotes angiogenesis in the dermal papilla and perifollicular microvasculatur independent of KATP opening
4.1 VEGF-A Upregulation
Vascular endothelial growth factor (VEGF-A) is a super important paracrine signal from DPCs to endothelial cells of the perifollicular capillary plexus. Minoxidil increases VEGF-A mRNA and protein in cultured DPCs within around 10 hrs i guess.
Mechanism (proposed):
I) Minoxidil sulfate inhibits lysyl hydroxylase (procollagen-lysine, 2-oxoglutarate 5-dioxygenase, PLOD). This enzyme hydroxylates lysine residues in collagen so inhibition leads to unfolded protein response (UPR) and activation of hypoxia inducible factor 1α (HIF 1 alpha)
II) HIF-1α escapes von Hippel-Lindau (VHL) mediated proteasomal degradation then translocates to the nucleus and binds hypoxia response elements (HREs) in the VEGF-A promoter.
III) This mimics a hypoxic state without actual oxygen deprivation
4.2 Prostaglandin Synthesis
Minoxidil also increases cyclooxygenase-1 (COX-1) activity in DPCs leading to elevated prostaglandin E2 (PGE2) and prostacyclin (PGI2). Both PGE2 and PGI2 are vasodilatory and pro angiogenic via EP2/EP4 and IP receptors.
4.3 Relevance to Hair Cycling
Anagen requires a dense perifollicular capillary network. during the transition from telogen to anagen angiogenesis precedes keratinocyte proliferation. minoxidil likely shortens the telogen-to-anagen transition time via VEGF mediated vascular remodeling
5. PROLONGATION OF ANAGEN PHASE
The hair cycle consists of three phases: anagen (growth), catagen (apoptosis driven regression), telogen (resting). In AGA, anagen progressively shortens with each cycle producing miniaturized vellus hairs.
5.1 Apoptosis Suppression
Minoxidil delays catagen entry by inhibiting programmed cell death in follicular keratinocytes.
Molecular mechanisms:
I) Increases Bcl-2/Bax ratio (anti apoptotic Bcl-2 upregulated and pro apoptotic Bax unchanged or slightly reduced).
II) Reduces caspase-3 activation (executioner caspase).
III) Suppresses p53-dependent apoptosis (p53 is a catagen triggering transcription factor in the follicle).
5.2 Matrix Keratinocyte Proliferation
Minoxidil directly stimulates proliferation of outer root sheath (ORS) keratinocytes and matrix cells in the hair bulb. this effect is independent of KATP (Kir6.1 is low in these cells) and instead mediated by:
I) ERK1/2 (MAPK pathway) activation (phosphorylation at Thr202/Tyr204).
II) PI3K/AKT pathway activation (phosphorylation at Ser473).
Both pathways converge on cyclin D1 upregulation promoting G1/S transition. View attachment 54045
6. β-CATENIN AND Wnt PATHWAY MODULATION
The canonical Wnt/β-catenin pathway is the master regulator of hair follicle morphogenesis and cycling. β-catenin stabilization in dermal papilla cells and keratinocytes is necessary and sufficient to induce anagen.
6.1 Mechanism of β-Catenin Stabilization
In the absence of Wnt signaling a destruction complex (Axin, APC, GSK3β, CK1α) phosphorylates β-catenin at Ser33/Ser37/Thr41 leading to ubiquitination (β-TrCP) and proteasomal degradation.
minox promotes β-catenin stabilization via: I) Inhibition of GSK3β (glycogen synthase kinase 3β) II) Reduced phosphorylation at Ser33/Ser37
Stabilized β-catenin translocates to the nucleus and complexes with TCF/LEF (T cell factor/lymphoid enhancer factor) transcription factors. the target genes are: I) Axin2 (negative feedback loop) II) Cyclin D1 (proliferation) III) LEF1 itself (positive feedback) IV) FGF18 (anagen maintenance and not initiation)
In the absence of Wnt signaling (or with minoxidil) hair follicles remain in telogen. Minoxidil induced β-catenin stabilization maybe sufficient to overcome endogenous Wnt inhibitors (DKK1, SFRP1) that are elevated in balding scalps View attachment 54046
7. MITOCHONDRIAL BIOGENESIS AND PGC-1α
a more recently described effect: minoxidil increases mitochondrial content and function in dermal papilla cells.
here PGC-1α (peroxisome proliferator activated receptor gamma coactivator 1-alpha) is the master regulator of mitochondrial biogenesis.
Mechanism:
I) Minoxidil elevates intracellular NAD+/NADH ratio
II) Increased NAD+ activates SIRT1 (sirtuin 1) which is an NAD+ dependent deacetylase.
III) SIRT1 deacetylates and activates PGC-1α.
IV) Activated PGC-1α coactivates NRF1 (nuclear respiratory factor 1) and NRF2 which drive transcription of mitochondrial DNA encoded genes (COX1, COX2, ATP6) and nuclear encoded mitochondrial genes (TFAM, TFB1M, TFB2M).
Consequence in DPCs: higher mitochondrial density supports the high metabolic demand of anagen phase follicles. DPCs from balding scalps show reduced mitochondrial membrane potential and increased ROS which minoxidil partially reverses View attachment 54052
1. HISTORICAL AND CLINICAL CONTEXT Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) was originally synthesized in the 1970s by the Upjohn Company (now Pfizer) as a peripheral vasodilator for severe, refractory hypertension. Its mechanism was basically opening ATP sensitive potassium channels (KATP) in vascular smooth muscle reducing systemic vascular resistance with minimal direct cardiac depression.
observation: within 3 to 6 months of oral administration the patients developed generalized hypertrichosis (excessive body hair), most pronounced on the face, arms and back. this side effect was dose dependent and reversible upon discontinuation.
subsequent topical formulation development (2%, 5%, 5% foam and 15% compounded solutions) targeted the scalp while minimizing systemic absorption. FDA approval for androgenetic alopecia occurred in 1988 (2%) and 1997 (5% for men and 2% for women).
clinical distinction: minoxidil is not an antiandrogen. It doesnt inhibit 5AR nor does it block the androgen receptor. It works entirely independently of the hormonal axis which explains why it is effective in both androgenic alopecia and alopecia areata albeit through completely different pathophysiological routes.
2. CHEMICAL STRUCTURE AND PRODRUG ACTIVATION
minoxidil as administered is a prodrug. It has negligible biological activity in its native form.
Structural features:
I) pyrimidine N-oxide (the 3-oxide group is critical for subsequent sulfation)
II) primary amine at position 2 and 4 (diamino)
III) piperidine ring at position 6
Pathway for bioactivation:
Minoxidil to Minoxidil sulfate (active form) via sulfotransferase enzymes, specifically SULT1A1 (cytosolic and phenol preferring) and maybe SULT1A3 in some tissues
The reaction transfers a sulfonate group (SO₃-) from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the N-oxide oxygen of minoxidil. the resulting minoxidil N-O-sulfate is a stable anion at physiological pH
Tissue specificity of activation:
Highest SULT1A1 expression is in liver (first pass metabolism), kidney, intestinal mucosa, dermal papilla cells and outer root sheath keratinocytes of the hair follicle
SULT1A1 activity varies interindividually by upto 10 fold due to genetic polymorphisms (like the SULT1A12 variant, R213H, reduces activity)
Why this matters:
non responders to topical minoxidil often have low SULT1A1 activity in scalp follicles. coadministration of tret upregulates SULT1A1 expression and minoxidil sulfation in vitro.
3. ION CHANNEL PHYSIOLOGY (KATP)
The primary established molecular target of minoxidil sulfate is the ATP sensitive potassium channel (KATP).
3.1 Channel Structure
KATP is an octameric complex of two distinct subunits: I) Kir6.0 (KCNJ8 for Kir6.1, KCNJ11 for Kir6.2): this one forms the potassium conducting pore. has a tetrameric assembly. II) SUR (sulfonylurea receptor, ABCC8 for SUR1, ABCC9 for SUR2): it's a regulatory subunit belonging to the ATP binding cassette (ABC) transporter family. binds nucleotides (ATP/ADP) and channel openers (including minoxidil sulfate, cromakalim, diazoxide)
Four SUR subunits associate with four Kir6.0 subunits (SURx4/Kir6.x4).
The relevant isoform for hair growth is SUR2B/Kir6.1 on dermal papilla cells (DPCs) and to a lesser extent outer root sheath keratinocytes
3.3 Mechanism of Channel Opening
Under normal physiological conditions, intracellular ATP closes KATP (that is why it's “ATP sensitive” lmao). high ATP/ADP ratio makes the channel close so the membrane gets depolarized. low ATP/ADP ratio causes channel to open which leads to hyperpolarization
Minoxidil sulfate binds to the SUR2B subunit at a site distinct from the nucleotide binding folds (specifically transmembrane helices 8-11 of SUR2).
Binding:
I) displaces inhibitory Mg ATP from SUR’s NBF2 (nucleotide binding fold 2)
II) stabilizes the open conformation of Kir6.1
III) allows potassium efflux even at normal or elevated ATP levels View attachment 54041
4. THE VEGF AXIS
Minoxidil promotes angiogenesis in the dermal papilla and perifollicular microvasculatur independent of KATP opening
4.1 VEGF-A Upregulation
Vascular endothelial growth factor (VEGF-A) is a super important paracrine signal from DPCs to endothelial cells of the perifollicular capillary plexus. Minoxidil increases VEGF-A mRNA and protein in cultured DPCs within around 10 hrs i guess.
Mechanism (proposed):
I) Minoxidil sulfate inhibits lysyl hydroxylase (procollagen-lysine, 2-oxoglutarate 5-dioxygenase, PLOD). This enzyme hydroxylates lysine residues in collagen so inhibition leads to unfolded protein response (UPR) and activation of hypoxia inducible factor 1α (HIF 1 alpha)
II) HIF-1α escapes von Hippel-Lindau (VHL) mediated proteasomal degradation then translocates to the nucleus and binds hypoxia response elements (HREs) in the VEGF-A promoter.
III) This mimics a hypoxic state without actual oxygen deprivation
4.2 Prostaglandin Synthesis
Minoxidil also increases cyclooxygenase-1 (COX-1) activity in DPCs leading to elevated prostaglandin E2 (PGE2) and prostacyclin (PGI2). Both PGE2 and PGI2 are vasodilatory and pro angiogenic via EP2/EP4 and IP receptors.
4.3 Relevance to Hair Cycling
Anagen requires a dense perifollicular capillary network. during the transition from telogen to anagen angiogenesis precedes keratinocyte proliferation. minoxidil likely shortens the telogen-to-anagen transition time via VEGF mediated vascular remodeling
5. PROLONGATION OF ANAGEN PHASE
The hair cycle consists of three phases: anagen (growth), catagen (apoptosis driven regression), telogen (resting). In AGA, anagen progressively shortens with each cycle producing miniaturized vellus hairs.
5.1 Apoptosis Suppression
Minoxidil delays catagen entry by inhibiting programmed cell death in follicular keratinocytes.
Molecular mechanisms:
I) Increases Bcl-2/Bax ratio (anti apoptotic Bcl-2 upregulated and pro apoptotic Bax unchanged or slightly reduced).
II) Reduces caspase-3 activation (executioner caspase).
III) Suppresses p53-dependent apoptosis (p53 is a catagen triggering transcription factor in the follicle).
5.2 Matrix Keratinocyte Proliferation
Minoxidil directly stimulates proliferation of outer root sheath (ORS) keratinocytes and matrix cells in the hair bulb. this effect is independent of KATP (Kir6.1 is low in these cells) and instead mediated by:
I) ERK1/2 (MAPK pathway) activation (phosphorylation at Thr202/Tyr204).
II) PI3K/AKT pathway activation (phosphorylation at Ser473).
Both pathways converge on cyclin D1 upregulation promoting G1/S transition. View attachment 54045
6. β-CATENIN AND Wnt PATHWAY MODULATION
The canonical Wnt/β-catenin pathway is the master regulator of hair follicle morphogenesis and cycling. β-catenin stabilization in dermal papilla cells and keratinocytes is necessary and sufficient to induce anagen.
6.1 Mechanism of β-Catenin Stabilization
In the absence of Wnt signaling a destruction complex (Axin, APC, GSK3β, CK1α) phosphorylates β-catenin at Ser33/Ser37/Thr41 leading to ubiquitination (β-TrCP) and proteasomal degradation.
minox promotes β-catenin stabilization via: I) Inhibition of GSK3β (glycogen synthase kinase 3β) II) Reduced phosphorylation at Ser33/Ser37
Stabilized β-catenin translocates to the nucleus and complexes with TCF/LEF (T cell factor/lymphoid enhancer factor) transcription factors. the target genes are: I) Axin2 (negative feedback loop) II) Cyclin D1 (proliferation) III) LEF1 itself (positive feedback) IV) FGF18 (anagen maintenance and not initiation)
In the absence of Wnt signaling (or with minoxidil) hair follicles remain in telogen. Minoxidil induced β-catenin stabilization maybe sufficient to overcome endogenous Wnt inhibitors (DKK1, SFRP1) that are elevated in balding scalps View attachment 54046
7. MITOCHONDRIAL BIOGENESIS AND PGC-1α
a more recently described effect: minoxidil increases mitochondrial content and function in dermal papilla cells.
here PGC-1α (peroxisome proliferator activated receptor gamma coactivator 1-alpha) is the master regulator of mitochondrial biogenesis.
Mechanism:
I) Minoxidil elevates intracellular NAD+/NADH ratio
II) Increased NAD+ activates SIRT1 (sirtuin 1) which is an NAD+ dependent deacetylase.
III) SIRT1 deacetylates and activates PGC-1α.
IV) Activated PGC-1α coactivates NRF1 (nuclear respiratory factor 1) and NRF2 which drive transcription of mitochondrial DNA encoded genes (COX1, COX2, ATP6) and nuclear encoded mitochondrial genes (TFAM, TFB1M, TFB2M).
Consequence in DPCs: higher mitochondrial density supports the high metabolic demand of anagen phase follicles. DPCs from balding scalps show reduced mitochondrial membrane potential and increased ROS which minoxidil partially reverses View attachment 54052
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
